# Frontline BioVentures

> Frontline BioVentures is a VC fund backing Health Care and Biotechnology. See 17 investments, check sizes, portfolio and contact details. Updated Oct 2026.

- Type: VC Fund
- Location: Shanghai, China
- Total investments: 17
- Last investment: May 2021
- Lead investor: 24%
- Last fund: Mar 2017
- Last updated: Oct 2026
- LinkedIn: https://www.linkedin.com/company/frontline-bioventures/about/

Frontline BioVentures is a VC fund in Shanghai focused on Health Care and Biotechnology. ###Frontline BioVentures merged with WuXi Healthcare Ventures to form 6 Dimensions Capital###Frontline BioVentures is a premier China-based venture capital firm specialize in the investment of innovative life science companiesWe focus on business within strategic life science and technology areas promoted by the Chinese government.Currentlywe manage two funds, a RMB denominated fund and a parallel USD fund, which offers structural flexibilities to best serve the needs of portfolio companies.

## Contacts

5 contacts available for Frontline BioVentures. Shizune tracks 1 team members at Frontline BioVentures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/frontline-bioventures?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 8 | 47% |
| Biotechnology | 6 | 35% |
| Medical | 4 | 24% |
| Pharmaceutical | 4 | 24% |
| Manufacturing | 3 | 18% |

14 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Venture - Series Unknown | 5 | 29% |
| Series B | 4 | 24% |
| Series C | 3 | 18% |
| Series A | 2 | 12% |
| Series D | 1 | 6% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 12 | 71% |
| United States | 3 | 18% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Lianyong Chen | Founder and Managing Partner | 5 | https://shizune.co/investors/profile/lianyong-chen |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Yikon Genomics | Yikon Genomics is a leading solution-based single cell sequencing company. Currently based on the patented MALBAC® technology from Harvard University, Yikon provides complete solutions in the fields of reproductive health and cancer diagnostics with liquid tumor biopsy. The MALBAC-PGS™ and MALBAC-PGD™ solutions offer the most accurate andcomprehensive embryo testing results for physicians to choose the best embryos with balanced chromosomal copy numbers,without inheriting the known disease-associated alleles. The MALBAC-PGS™ and MALBAC-PGD™ solutions have helped thousands of couples to achieve successful pregnancies. Yikon will continue to interpret the code of life and bring people the hope and joy of life. | $38.7M | Series D | May 06, 2021 | http://www.yikongenomics.com |
| GKHT Medical Technology | Guoke Hengtai (Beijing) Medical Technology Co., Ltd. was established in February 2013 and is affiliated to Oriental Science and Technology Holding Group Co., Ltd. (hereinafter referred to as “Oriental Instrument”), a subsidiary of the State-owned Assets Supervision and Administration Commission of the Chinese Academy of Sciences. It isheadquartered in Yizhuang Economic and Technological Development Zone, Beijing. . Since the establishment of Guoke Hengtai for 4 years, the company has experienced two rounds of investment in A and B, and its performance has continued to grow at a high speed, with a compound annual growth rate of over 50%. In 2017, the company officially launched the IPO listing journey. | $154.5M | Series C | Sep 09, 2019 | http://www.heng-tai.com.cn/ |
| Sinopharm Online | Sinopharm Online has a pharmaceutical retail platform to provide users with online medication consultation, medical and health management consulting services, etc. The main sales cover Chinese and Western medicines and health products. , medical equipment, Chinese medicine | $44.6M | Series B | Apr 26, 2019 | http://www.sinopharm.com/ |
| Shenzhen Dano Pharmaceuticals | Shenzhen Dano Pharmaceuticals specializes in the development, manufacturing and marketing of pharmaceutical API. |  | Venture - Series Unknown | Jan 01, 2019 | http://www.danopharma.cn/lxwm |
| Ultivue | Ultivue is a biotechnology company that specializes in tissue imaging, diagnostics, and multiplexing. Ultivue produces reagents that enable researchers to obtain microscopic images at an unprecedented resolution that helps to understand of biology and medicine. Ultivue's products are designed for fluorescent microscopy-based research and willeventually be valuable for clinical diagnostic use. It was founded in 2015 and headquartered in Cambridge, Massachusetts. | $20M | Series B | Jan 23, 2018 | http://www.ultivue.com/ |
| Yidebang | Yidebang is a Beijing-based healthcare software developer, which provides management solution, drug supply, hierarchical diagnosis and treatment and other supporting medical services for basic-level clinics in China. | $9M | Series A | Nov 09, 2017 | http://www.yideb.com/ |
| Cutagen | Cutagen is a Operator of a specialty medical device company focused on advanced wound and skin care for clinical use and cosmetic applications. The company's products provide a local hyperoxic environment to facilitate the healing and management of injured tissues of skin or oral mucosa and the improvement in the appearance of skin. |  | Venture - Series Unknown | Jan 01, 2017 |  |
| TenNor Therapeutics | TenNor Therapeutics is a clinical stage, product development company with a sharp focus on unmet medical needs in the area of infectious diseases. The company possesses a dual-acting drug discovery platform with several innovative products in various stages of preclinical and clinical development. The company is developing new drugs for thetreatment of Helicobacter pylori infections, prosthetic joint infections, multidrug-resistant Gram-negative infections and some other common and serious infectious diseases. | $25M | Series B | Sep 19, 2016 | http://www.tennorx.com/ |
| Hua Medicine | Hua Medicine is a clinical-stage, innovative drug development company in China, focused on novel therapies for the treatment of diabetes and CNS disorders. Founded by pharma industry veterans and funded by a premier group of international VC investment firms such as Fidelity Asia, Fidelity Biosciences, ARCH Ventures, Venrock, SAIL and WuXiVentures, the company has in-licensed from major pharma, world-wide rights to a potential best-in-class, oral drug for the treatment of Type 2 Diabetes which utilizes a novel mechanism of action. | $50M | Series C | Apr 21, 2016 | https://www.huamedicine.com |
| Coherent Biopharma | Coherent Biopharma is a pahrmaceutical based agency. | $8M | Series A | Feb 01, 2016 | https://www.coherentbio.com |

10 of 17 investments shown.

## Co-investors
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 3 deals together
- [Venrock](https://shizune.co/investors/profile/venrock) — VC Fund, 3 deals together
- [WuXi Healthcare Ventures](https://shizune.co/investors/profile/wuxi-healthcare-ventures) — VC Fund, 3 deals together
- [6 Dimensions Capital](https://shizune.co/investors/profile/6-dimensions-capital) — VC Fund, 2 deals together
- [Ally Bridge Group](https://shizune.co/investors/profile/ally-bridge-group) — VC Fund, 2 deals together
- [CPP Investments](https://shizune.co/investors/profile/canada-pension-plan-investment-board) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Bossa Invest](https://shizune.co/investors/profile/bossanova-investimentos) — VC Fund
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [Gaingels](https://shizune.co/investors/profile/gaing) — VC Fund

## FAQ

### What does Frontline BioVentures invest in?

Frontline BioVentures invests primarily in Health Care, Biotechnology and Medical startups, most often at Venture - Series Unknown and Series B stage. Most of the 17 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Frontline BioVentures?

Public channels for Frontline BioVentures include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Frontline BioVentures?

The team at Frontline BioVentures includes Lianyong Chen (Founder and Managing Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co